Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment

Access through your institution Buy or subscribe Patients who receive cytotoxic chemotherapy and/or radiation therapy for breast cancer are at risk for developing therapy-related myeloid

neoplasms (t-MN), which include acute myeloid leukemia (t-AML), myelodysplastic syndrome (t-MDS) and myelodysplastic/myeloproliferative neoplasms (t-MDS/MPN).1 Indeed, breast cancer ranks

among the most common malignant solid tumors in patients who develop t-MN in population-based analyses.2, 3 Although several studies have addressed the impact of chemotherapy and radiation

therapy on t-MN development in patients with breast cancer, prognostic modeling to assess the risk of t-MN in patients with breast cancer treated with modern approaches has been hampered by

a lack of systematic analyses that simultaneously take into consideration demographics and patient comorbidities, primary malignancy factors, including therapy with novel antiestrogen

agents, as well as the characteristics of t-MDS/MPN. To bridge this knowledge gap, we conducted a comprehensive single-institution case–control study with institutional review board approval

to assess the demographic, biological and therapeutic features of patients with breast cancer who subsequently developed t-MN. This is a preview of subscription content, access via your

institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I _et al_. Therapy-related

myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H _et al_. (eds). _WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues_. IARC: Lyon,

France, 2008; pp 214–217. Google Scholar  * Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES _et al_. Evolving risk of therapy-related acute myeloid leukemia following cancer

chemotherapy among adults in the United States, 1975-2008. _Blood_ 2013; 121: 2996–3004. Article  CAS  PubMed  PubMed Central  Google Scholar  * Ramadan SM, Suciu S, Stevens-Kroef MJPL,

Willemze R, Amadori S, Witte Td _et al_. Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON Leukemia Group

Trials. _Blood_ 2013; 122: 829a. Google Scholar  * Khoury JD, Sen F, Abruzzo LV, Hayes K, Glassman A, Medeiros LJ . Cytogenetic findings in blastoid mantle cell lymphoma. _Hum Pathol_ 2003;

34: 1022–1029. Article  CAS  PubMed  Google Scholar  * Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K _et al_. Clinical relevance of cancer stem cells in bone marrow of early

breast cancer patients. _Ann Oncol_ 2013; 24: 2515–2521. Article  CAS  PubMed  PubMed Central  Google Scholar  * O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E _et

al_. Acute myeloid leukemia. _J Natl Compr Cancer Netw_ 2012; 10: 984–1021. Article  CAS  Google Scholar  * Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F _et al_.

Revised international prognostic scoring system for myelodysplastic syndromes. _Blood_ 2012; 120: 2454–2465. Article  CAS  PubMed  PubMed Central  Google Scholar  * Rosato V, Bosetti C,

Talamini R, Levi F, Montella M, Giacosa A _et al_. Metabolic syndrome and the risk of breast cancer in postmenopausal women. _Ann Oncol_ 2011; 22: 2687–2692. Article  CAS  PubMed  Google

Scholar  * Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C _et al_. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. _J Natl Cancer Inst_

2003; 95: 1218–1226. Article  CAS  PubMed  Google Scholar  * Balkwill F, Charles KA, Mantovani A . Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

_Cancer Cell_ 2005; 7: 211–217. Article  CAS  PubMed  Google Scholar  * Kaye JA, Meier CR, Walker AM, Jick H . Statin use, hyperlipidaemia, and the risk of breast cancer. _Br J Cancer_

2002; 86: 1436–1439. Article  CAS  PubMed  PubMed Central  Google Scholar  * Liao S, Li J, Wei W, Wang L, Zhang Y, Li J _et al_. Association between diabetes mellitus and breast cancer risk:

a meta-analysis of the literature. _Asian Pac J Cancer Prev_ 2011; 12: 1061–1065. PubMed  Google Scholar  * Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M _et al_.

Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. _Cancer_ 2005; 103: 1122–1128. Article  CAS  PubMed  Google

Scholar  * Armand P, Kim HT, Mayer E, Cutler CS, Ho VT, Koreth J _et al_. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. _Bone Marrow Transplant_ 2010;

45: 1611–1617. Article  CAS  PubMed  PubMed Central  Google Scholar  * Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS _et al_. Role of TP53 mutations in the origin and evolution

of therapy-related acute myeloid leukaemia. _Nature_ 2014; 518: 552–555. Article  PubMed  PubMed Central  Google Scholar  Download references ACKNOWLEDGEMENTS This work was supported by the

National Cancer Institute (CA016672, MD Anderson Cancer Center Support Grant); the Slovak Grant Agency (VEGA 1/0724/11 to MM); and the Slovak Research and Development Agency (APVV-0016-11

to KS and MM). We thank Sherry Pierce (Leukemia) and Limin Hsu (Breast Medical Oncology) for assistance with database queries. We also thank Leiloni Gilbert for administrative support.

AUTHOR CONTRIBUTIONS Khoury: Conception and design of study, data analysis, and manuscript preparation. Sevcikova and Zuo: Data collection, data analysis, and manuscript preparation. Zuo:

Statistical analysis. Garcia-Manero, Alvarez, Kantarjian, Mego, Albarracin, Tang, Strom, Medeiros, Hortobagyi, and Reuben: Data analysis and manuscript preparation. All the authors read and

approved the final manuscript. AUTHOR INFORMATION Author notes * R H Alvarez Present address: 8Present address: Cancer Treatment Centers of America, Atlanta, GA, USA., AUTHORS AND

AFFILIATIONS * Department of Medical Oncology, Comenius University, Faculty of Medicine, St Elizabeth Cancer Institute, Bratislava, Slovak Republic K Sevcikova * Department of

Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Z Zhuang, G Tang, L J Medeiros, J M Reuben & J D Khoury * Department of Leukemia, The University of

Texas MD Anderson Cancer Center, Houston, TX, USA G Garcia-Manero & H M Kantarjian * Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston,

TX, USA R H Alvarez & G N Hortobagyi * Second Department of Medical Oncology, Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovak Republic M Mego *

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA C Albarracin * Department of Epidemiology, The University of Texas MD Anderson Cancer Center,

Houston, TX, USA S S Strom Authors * K Sevcikova View author publications You can also search for this author inPubMed Google Scholar * Z Zhuang View author publications You can also search

for this author inPubMed Google Scholar * G Garcia-Manero View author publications You can also search for this author inPubMed Google Scholar * R H Alvarez View author publications You can

also search for this author inPubMed Google Scholar * H M Kantarjian View author publications You can also search for this author inPubMed Google Scholar * M Mego View author publications

You can also search for this author inPubMed Google Scholar * C Albarracin View author publications You can also search for this author inPubMed Google Scholar * G Tang View author

publications You can also search for this author inPubMed Google Scholar * S S Strom View author publications You can also search for this author inPubMed Google Scholar * L J Medeiros View

author publications You can also search for this author inPubMed Google Scholar * G N Hortobagyi View author publications You can also search for this author inPubMed Google Scholar * J M

Reuben View author publications You can also search for this author inPubMed Google Scholar * J D Khoury View author publications You can also search for this author inPubMed Google Scholar

CORRESPONDING AUTHOR Correspondence to J D Khoury. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. ADDITIONAL INFORMATION This work has been presented at

the 2014 American Society for Hematology annual meeting and the Society for Hematology and Oncology annual meeting. Supplementary Information accompanies this paper on the Leukemia website

SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION (DOC 194 KB) RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sevcikova, K., Zhuang, Z.,

Garcia-Manero, G. _et al._ Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. _Leukemia_ 30, 243–247

(2016). https://doi.org/10.1038/leu.2015.122 Download citation * Published: 15 May 2015 * Issue Date: January 2016 * DOI: https://doi.org/10.1038/leu.2015.122 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative